Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company, in collaboration with Loxo Oncology Inc., is conducting a Phase 3 study titled 'A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)'. The study aims to evaluate the efficacy and safety of the experimental drug Pirtobrutinib compared to the standard treatment of Bendamustine plus Rituximab in patients who have not received prior treatment for CLL/SLL.
The study tests two interventions: Pirtobrutinib, an oral medication, and a combination of Bendamustine and Rituximab, administered intravenously. Pirtobrutinib is being evaluated for its potential to offer a more effective and safer treatment option.
This interventional study is randomized with a parallel assignment model. Participants are divided equally into two groups, with no masking involved. The primary purpose is treatment, allowing crossover for patients with disease progression.
The study began on September 23, 2021, with an active but not recruiting status. The last update was submitted on July 22, 2025, indicating ongoing progress. These dates are crucial for tracking the study's development and anticipated results.
The outcome of this study could significantly impact Eli Lilly's and Loxo Oncology's stock performance by potentially introducing a new treatment option in the CLL/SLL market. This could influence investor sentiment positively, especially if Pirtobrutinib proves to be a superior treatment. Competitors in the oncology space will be closely monitoring these developments.
The study remains active, with further details available on the ClinicalTrials portal.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
29 minutes ago
- National Post
Tentative Agreement Reached at Villa Colombo Homes for the Aged
TORONTO — Negotiations between CUPE 5525 and Villa Colombo Homes for the Aged concluded Friday evening with the parties reaching a tentative agreement. The 10-week-old strike could come to an end as early as August 8 th, pending ratification of the agreement by both parties.
National Post
29 minutes ago
- National Post
Cinelease Acquired by Zello to Power the Next Era of Global Film & TV Production
Strategic acquisition expands production infrastructure, strengthens industry relationships, and unlocks scale across North America Article content LOS ANGELES — Zello, a private investment platform focused on scaling exceptional businesses in the broader entertainment industry, announced today that it has acquired Cinelease, a market leader in lighting and grip rentals, from Herc Rentals (NYSE: HRI). The transaction marks a defining move in Zello's strategy to support the infrastructure behind content creation — and power the future of global film and television production. Article content For over 45 years, Cinelease has been a trusted name in production support— renowned for its reliability, deep industry relationships, and service-first mindset. Under Zello's ownership, the company will continue to be led by industry veterans Mark Lamberton, Chris Rogers, and Gannon Murphy. Built on core values of responsiveness, dependability, and drive, Cinelease offers a robust inventory of lighting and grip equipment and serves as the professional manager of studio facilities owned by leading real estate investors. With operations spanning every major production hub in the U.S. and Canada, Cinelease supports thousands of film, television, and commercial productions annually through its integrated studio and equipment offerings. Article content Cinelease will operate as a standalone, privately held company backed by Zello's experienced team. With decades of operational expertise across studio management, equipment logistics, and production infrastructure, Zello will support Cinelease in deepening its market presence while remaining aligned with the needs of filmmakers and crews. This transition positions the company for disciplined expansion and reinforces its commitment to delivering world-class lighting, grip, and studio solutions. Article content 'Cinelease is built on trust—and a team that studios, crews, and producers have relied on for decades,' said Louis Dargenzio, CEO of Zello. 'This acquisition is about honoring that legacy while leaning into the future. We believe in this team, we believe in this brand, and we believe in the entertainment industry. We're excited to drive innovation and growth for our studio and production partners.' Article content 'This marks an exciting new chapter for Cinelease,' said Mark Lamberton, President of Cinelease. 'We're a company built on service, relationships, and delivering when it counts—led by people with a deep understanding of what it takes to make it happen. Zello brings deep respect for our foundation and the operational scale to help us go even further for the entertainment community. Together, we'll keep raising the bar for production support across North America.' Article content Zello was advised by Proskauer Rose LLP as legal counsel, EY as accounting advisor, and American Discovery Capital as financial advisor. Financing for the transaction was provided by MidCap Financial, a leading middle-market lender owned and managed by Apollo Global Management. Herc was advised by Sidley Austin LLP on legal matters and Goldman Sachs on financial matters. MidCap Financial was advised by Paul Hastings LLP on legal matters. Article content Article content About Cinelease Article content Founded in 1977, Cinelease is one of the most trusted names in production support—recognized for its reliability, deep industry relationships, and unwavering commitment to service. With operations across every major production hub in the U.S. and Canada, Cinelease supplies lighting and grip rentals, expendables, and sound stages to thousands of film, television, and commercial productions each year. Article content Cinelease also serves as the professional manager of studio facilities owned by leading real estate investors, offering an integrated platform that combines best-in-class equipment and scalable studio solutions. Its foundation is built on responsiveness, dependability, and drive—delivered by a deeply experienced team with an average tenure of over a decade. Article content From humble beginnings as a mom-and-pop operation to its evolution as an industry leader, Cinelease has remained true to its service-first ethos. Its culture is rooted in loyalty, collaboration, and a passion for supporting storytellers at every stage of production. Article content Zello is a next-generation investment platform where capital, creativity, and operational excellence converge. With core focus areas in content, high-growth businesses, and infrastructure, Zello builds, owns, and scales companies that power industries—starting with entertainment and expanding beyond. Article content Through an integrated approach, Zello combines disciplined investment, physical assets, and seasoned operating talent to scale proven models and back bold ideas. The platform is purpose built to help exceptional teams unlock long-term value and build enduring businesses. Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content
Globe and Mail
29 minutes ago
- Globe and Mail
Is Viking Therapeutics the Next Big Biotech Bet?
Explore the exciting world of Viking Therapeutics (NASDAQ: VKTX) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jul. 9, 2025. The video was published on Aug. 1, 2025. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
